Cisplatin and continuous infusion vindesine and 5-fluorouracil in non-small cell lung cancer (NSCLC) (ATTIT 002) . ATTIT (Association pour le Traitment des Tumeurs Intra-Thoraciques)
Riggi, M.; Cvitkovic, E.; de Cremoux, H.; Ruffie, P.; Monnet, I.; Voisin, S.; Villalobos, W.; Azli, N.; Saltiel, J.C.
European Journal of Cancer 29a(13): 1914-1915
1993
ISSN/ISBN: 0959-8049 PMID: 8260254 Document Number: 415381
Document emailed within 1 workday
Related Documents
Monnet, I.; Brienza, S.; Hugret, F.; Voisin, S.; Gastiaburu, J.; Saltiel, J.C.; Soulié, P.; Armand, J.P.; Cvitkovic, E.; de Cremoux, H. 1998: Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques European Journal of Cancer 34(7): 1124-1127Saito, Y.; Mori, K.; Tominaga, K.; Yokoi, K.; Miyazawa, N. 1991: Five-day continuous infusion of vindesine in the treatment of non-small cell lung cancer--clinical pharmacokinetics of vindesine Gan to Kagaku Ryoho. Cancer and ChemoTherapy 18(12): 2129-2132
Seike, M.; Andoh, M.; Hasegawa, K.; Sakonji, M.; Tsuboi, E. 1998: Combination chemotherapy with continuous infusion of low-dose cisplatin and UFT for advanced non-small cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 25(10): 1539-1542
Williams, C.J.; Woods, R.; Levi, J.; Page, J. 1988: Chemotherapy for non-small cell lung cancer: a randomized trial of cisplatin/vindesine v no chemotherapy Seminars in Oncology 15(6 Suppl 7: 58-61
Sasaki, K.; Hirata, K.; Denno, R.; Oikawa, I.; Mukaiya, M.; Hiraike, N.; Yagihashi, A.; Takasaka, H.; Katsuramaki, T.; Yamashiro, K.; Yamamitsu, S.; Shirasaka, T. 1997: Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 24(8): 959-964
Fujii, S.; Nakajima, K.; Ueno, K.; Sugai, Y.; Adachi, M. 1989: A case of intra-arterial infusion chemotherapy in small cell lung cancer with liver metastases Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(11): 3627-3630
Asano, M.; Mori, T.; Takahashi, K.; Yasuno, M. 1997: Low-dose cisplatin added to continuous infusion of 5-fluorouracil or oral administration of UFT for inoperable advanced or recurrent colorectal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 24(1): 55-60
Yoshimori, K. 2002: Non-small cell lung cancer (NSCLC) Nihon Rinsho. Japanese Journal of Clinical Medicine 60(Suppl 5): 294-297
Treat, J.; Greenberg, R.; Bratschi, J.; Gorman, G.; Meehan, L.; Friedland, D. 1994: First hints in non-small cell lung cancer (NSCLC) Leukemia 8(Suppl): S55-S58
Chang, A.Y.; Witte, R.S.; Tormey, D.C.; Ramirez, G. 1984: Evaluation of vindesine in patients with refractory small cell lung cancer Cancer Treatment Reports 68(11): 1407-1408
Yokoyama, A. 1999: Gemcitabine hydrochloride is a new anti-cancer agent which will be available in the patients with non-small cell lung cancer (NSCLC) in Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 26(7): 908-915
Schmidt, S.; Nestle, U.; Walter, K.; Licht, N.; Ukena, D.; Schnabel, K.; Kirsch, C.M. 2002: Optimization of radiotherapy planning for non-small cell lung cancer (NSCLC) using 18FDG-PET NUKLEARMEDIZIN. Nuclear Medicine 41(5): 217-220
Nishimura, M.; Sugiura, T.; Urata, A.; Ota, K. 1985: Current status in the treatment of inoperable non-small cell lung cancer (NSCLC) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 12(1): 54-60
Pathak, A.K.; Bhutani, M.; Mohan, A.; Guleria, R.; Bal, S.; Kochupillai, V. 2004: Non small cell lung cancer (NSCLC): current status and future prospects Indian Journal of Chest Diseases and Allied Sciences 46(3): 191-203
Low, J.Sh.; Koh, W.Yao.; Yap, S.Peng.; Fong, K.Weng. 2007: Radical radiotherapy in stage I non-small cell lung cancer (NSCLC)--Singapore National Cancer Centre experience Annals of the Academy of Medicine Singapore 36(9): 778-783
Armand, J.P. 2000: Docetaxel (Taxotere) in the treatment of non-small cell lung cancer (NSCLC)--is there a role for a new chemotherapy programme? Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27 Suppl. 2: 223-230
Clement, D.; Miron, L.; Marinca, M. 2007: Age-related prognostic factors and treatment results for advanced non-small cell lung cancer (NSCLC) Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 111(4): 856-863
Ratanatharathorn, V.; Jirajarus, M.; Sirachainan, E.; Sirilerttrakul, S.; Euaree, A.; Supatchaipisit, P. 1998: Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer (NSCLC): a preliminary study Journal of the Medical Association of Thailand 81(10): 763-771
Liu, Y.-q.; Guo, R.-h.; Liu, L.-k.; Gao, W.; Zhu, C.-j.; Wei, J.; Shu, Y.-q. 2011: Correlation between expression of forkhead box M1 (FOXM1) and clinicopathological features and prognosis in patients with non-small cell lung cancer (NSCLC) Zhonghua Zhong Liu Za Zhi 33(6): 426-430
Takezako, Y.; Okusaka, T.; Ueno, H.; Ikeda, M.; Morizane, C.; Najima, M. 2008: Phase Ii study of cisplatin, epirubicin and continuous infusion of 5-fluorouracil in patients with advanced intrahepatic cholangiocellular carcinoma (ICC) Hepato-Gastroenterology 55(85): 1380-1384